Isotretinoin was authorized since 1982 for the treatment of acne vulgaris associated to severe cutaneous lesions. It has been used in others clinical conditions in various plans of prescription. Since the Isotretinoin was launched, it caused controversies in our country and around the world, especially in relation with the security. Isotretinoin is proscribed in pregnant patient. As a security rule we must measure serum lipids and hepatic enzymes. The aim of the consensus was to spread information worked by a group of Mexican experienced dermatologists to the health professionals about the use and the specific indications about isotretinoin.